Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
MyChesCo on MSN5h
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
The five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback